GI Esophageal / Gastric

Adjuvant

IRB #16058
A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer (CheckMate 577: CHECKpoint pathway and nivolumab clinical Trial Evaluation 577)

IRB #12071
New study to be available soon

IRB #16893
New study to be available soon

IRB# 18147
New study to be available soon

IRB #18340
New study to be available soon

Localized

HER 2+

1st Line

No Trials Currently Available

2nd Line

HER 2-

1st Line

2nd Line

Metastatic

IRB #18147
New study to be available soon

Key

- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php